Top-line data for the IVF drug look promising but what investors really want to see are the Phase III data for ObsEva's lead product expected later this year in the much larger uterine fibroid market.
ObsEva SA's oral oxytocin inhibitor nolasiban may be able to increase the chances of a successful pregnancy following IVF treatment, suggest top-line Phase III data. The company claims the product (previously known as OBE001) could be one of the biggest leaps forward in infertility treatment in decades but more studies are needed before it is likely to reach the market.
Initial results from the IMPLANT2 study show an increase in ongoing pregnancy rate at week 10 in patients undergoing in...
The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.
Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.
Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.
Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
